By Kelly Cloonan
AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial.
The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin.
In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said.
Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said.
The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting.
Write to Kelly Cloonan at kelly.cloonan@wsj.com